Search Results

Filter
  • 1-10 of  522 results for ""Ustekinumab""
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Relative efficacy and safety of apremilast, secukinumab, and ustekinumab for the treatment of psoriatic arthritis.

  • Authors : Song GG; Division of Rheumatology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, 73, Inchon-ro, Seongbuk-gu, 136-705, Seoul, Korea (Republic of).; Lee YH

Subjects: Antibodies, Monoclonal*/Antibodies, Monoclonal*/Antibodies, Monoclonal*/adverse effects ; Antibodies, Monoclonal*/Antibodies, Monoclonal*/Antibodies, Monoclonal*/therapeutic use ; Antirheumatic Agents*/Antirheumatic Agents*/Antirheumatic Agents*/adverse effects

  • Source: Zeitschrift fur Rheumatologie [Z Rheumatol] 2018 Sep; Vol. 77 (7), pp. 613-620.Publisher: Springer Country of Publication: Germany NLM ID: 0414162 Publication Model: Print Cited Medium: Internet

Record details

×
Academic Journal

Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study.

  • Authors : Chimenti MS; Rheumatology, Allergology and Clinical Immunology, Department of 'Medicina dei Sistemi', University of Rome Tor Vergata, Rome, Italy.; Ortolan A

Subjects: Antirheumatic Agents/Antirheumatic Agents/Antirheumatic Agents/*therapeutic use ; Arthritis, Psoriatic/Arthritis, Psoriatic/Arthritis, Psoriatic/*drug therapy ; Ustekinumab/Ustekinumab/Ustekinumab/*therapeutic use

  • Source: Clinical rheumatology [Clin Rheumatol] 2018 Feb; Vol. 37 (2), pp. 397-405. Date of Electronic Publication: 2018 Jan 04.Publisher: Springer Country of Publication: Germany NLM ID: 8211469 Publication Model: Print-Electronic Cited Medium:

Record details

×
Academic Journal

Challenges in longitudinal exposure-response modeling of data from complex study designs: a case study of modeling CDAI score for ustekinumab in patients with Crohn's disease.

  • Authors : Hu C; Global Clinical Pharmacology, Janssen Research & Development, LLC, 1400 McKean Road, PO Box 776, Spring House, PA, 19477, USA. .; Adedokun OJ

Subjects: Dose-Response Relationship, Drug* ; Models, Biological* ; Research Design*

  • Source: Journal of pharmacokinetics and pharmacodynamics [J Pharmacokinet Pharmacodyn] 2017 Oct; Vol. 44 (5), pp. 425-436. Date of Electronic Publication: 2017 Jun 16.Publisher: Springer Country of Publication: United States NLM ID: 101096520 Publication Model: Print-Electronic Cited Medium:

Record details

×
Academic Journal

Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE).

  • Authors : Iannone F; Department of Emergency and Organ Transplantation-Rheumatology Unit, Policlinico, University of Bari, Piazza G. Cesare 11, 70124, Bari, Italy. .; Santo L

Subjects: Antirheumatic Agents/Antirheumatic Agents/Antirheumatic Agents/*therapeutic use ; Arthritis, Psoriatic/Arthritis, Psoriatic/Arthritis, Psoriatic/*drug therapy ; Ustekinumab/Ustekinumab/Ustekinumab/*therapeutic use

  • Source: Clinical rheumatology [Clin Rheumatol] 2018 Mar; Vol. 37 (3), pp. 667-675. Date of Electronic Publication: 2018 Feb 07.Publisher: Springer Country of Publication: Germany NLM ID: 8211469 Publication Model: Print-Electronic Cited Medium:

Record details

×
Academic Journal

Minimal disease activity in patients with psoriatic arthritis treated with ustekinumab: results from a 24-week real-world study.

  • Authors : Napolitano M; Department of Medicine and Health Science 'Vincenzo Tiberio', University of Molise, Campobasso, Italy. .; Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini, 5, 80131, Naples, Italy. .

Subjects: Antirheumatic Agents/Antirheumatic Agents/Antirheumatic Agents/*therapeutic use ; Arthritis, Psoriatic/Arthritis, Psoriatic/Arthritis, Psoriatic/*drug therapy ; Dermatologic Agents/Dermatologic Agents/Dermatologic Agents/*therapeutic use

  • Source: Clinical rheumatology [Clin Rheumatol] 2017 Jul; Vol. 36 (7), pp. 1589-1593. Date of Electronic Publication: 2017 May 31.Publisher: Springer Country of Publication: Germany NLM ID: 8211469 Publication Model: Print-Electronic Cited Medium:

Record details

×
Academic Journal

Treatment with ustekinumab in a Spanish cohort of patients with psoriasis and psoriatic arthritis in daily clinical practice.

Subjects: Arthritis, Psoriatic/Arthritis, Psoriatic/Arthritis, Psoriatic/*drug therapy ; Psoriasis/Psoriasis/Psoriasis/*drug therapy ; Ustekinumab/Ustekinumab/Ustekinumab/*therapeutic use

  • Source: Clinical rheumatology [Clin Rheumatol] 2017 Feb; Vol. 36 (2), pp. 439-443. Date of Electronic Publication: 2016 Nov 05.Publisher: Springer Country of Publication: Germany NLM ID: 8211469 Publication Model: Print-Electronic Cited Medium:

Record details

×
Report

Treatment of CGD-associated Colitis with the IL-23 Blocker Ustekinumab.

  • Authors : Butte MJ; Division of Allergy, Immunology, and Rheumatology, Department of Pediatrics, Stanford University, 300 Pasteur Drive, Grant Building Room H307A, Stanford, CA, 94305, USA. .; Park KT

Subjects: Colitis/Colitis/Colitis/*drug therapy ; Granulomatous Disease, Chronic/Granulomatous Disease, Chronic/Granulomatous Disease, Chronic/*complications ; Ustekinumab/Ustekinumab/Ustekinumab/*therapeutic use

  • Source: Journal of clinical immunology [J Clin Immunol] 2016 Oct; Vol. 36 (7), pp. 619-20. Date of Electronic Publication: 2016 Jul 27.Publisher: Springer Country of Publication: Netherlands NLM ID: 8102137 Publication Model: Print-Electronic Cited Medium:

Record details

×
Academic Journal

Effectiveness of ustekinumab in patients with psoriatic arthritis in a real-world, multicenter study.

Subjects: Antirheumatic Agents*/Antirheumatic Agents*/Antirheumatic Agents*/therapeutic use ; Arthritis, Psoriatic*/Arthritis, Psoriatic*/Arthritis, Psoriatic*/drug therapy ; Psoriasis*/Psoriasis*/Psoriasis*/drug therapy

  • Source: Clinical rheumatology [Clin Rheumatol] 2020 Oct; Vol. 39 (10), pp. 2963-2971. Date of Electronic Publication: 2020 Apr 13.Publisher: Springer Country of Publication: Germany NLM ID: 8211469 Publication Model: Print-Electronic Cited Medium:

Record details

×
Academic Journal

Cutaneous vasculitis associated with molecular tergeted therapies: systematic review of the literature.

  • Authors : Ak T; Department of Internal Medicine, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Kocamustafapasa str., Number: 53, Cerrahpasa 34098 Fatih, Istanbul, Turkey. .; Durmus RB

Subjects: Antineoplastic Agents* ; Skin Diseases, Vascular*/Skin Diseases, Vascular*/Skin Diseases, Vascular*/chemically induced ; Skin Diseases, Vascular*/Skin Diseases, Vascular*/Skin Diseases, Vascular*/drug therapy

  • Source: Clinical rheumatology [Clin Rheumatol] 2023 Feb; Vol. 42 (2), pp. 339-357. Date of Electronic Publication: 2022 Nov 12.Publisher: Springer Country of Publication: Germany NLM ID: 8211469 Publication Model: Print-Electronic Cited Medium:

Record details

×
Academic Journal

Improving categorical endpoint longitudinal exposure-response modeling through the joint modeling with a related endpoint.

  • Authors : Hu C; Clinical Pharmacology and Pharmacometrics, Janssen Research & Development, LLC, 1400 McKean Road, PO Box 776, Spring House, PA, 19477, USA. .; Zhou H

Subjects: Psoriasis*/Psoriasis*/Psoriasis*/drug therapy; Humans ; Double-Blind Method

  • Source: Journal of pharmacokinetics and pharmacodynamics [J Pharmacokinet Pharmacodyn] 2022 Jun; Vol. 49 (3), pp. 283-291. Date of Electronic Publication: 2021 Nov 20.Publisher: Springer Country of Publication: United States NLM ID: 101096520 Publication Model: Print-Electronic Cited Medium:

Record details

×
  • 1-10 of  522 results for ""Ustekinumab""